brolucizumab
tislelizumab
abagovomab
pidilizumab
cergutuzumab
muromonab
antistreptavidin
antinucleosome
conatumumab
autocentromere
cross-reactivity
-toxa-
oleclumab
naptumomab estafenatox
anti-nuclear factor
elsilimomab
otelixizumab
immunosorbing
heteroclitic
fluorescein isothiocyanate
teneliximab
drozitumab
polyvalent
immunomodulant
cedelizumab
fluorescein isocyanate
serospecific
fontolizumab
tocilizumab
zanolimumab
antimonoclonal
polyantibody
patritumab
precipitin
immunoprobe
sarilumab
talizumab
mepolizumab
antitoxin
antihaemolysin
ozogamicin
retifanlimab
sintilimab
toripalimab
vanucizumab
zenocutuzumab
sasanlimab
pozelimab
solitomab
dinutuximab